{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Talebian H"],"funding":["New Frontiers in Research Fund - Transformation"],"pagination":["11651"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12692291"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(23)"],"pubmed_abstract":["Prostate cancer (PCa), particularly in its metastatic form, remains a major clinical challenge due to limited diagnostic and therapeutic options. To address this, we developed a novel radiotheranostic agent, [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA, by conjugating a prostate-specific membrane antigen (PSMA) ligand to a <sup>64</sup>Cu-radiolabeled terpyridine-platinum (TP) compound previously shown to exert selective cytotoxicity against cancer cells. In this study, the biological performance of [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA was compared with the monomeric analogs [<sup>64</sup>Cu]Cu-NOTA-PSMA and [<sup>64</sup>Cu]Cu-NOTA-TP through in vitro studies in PSMA-positive LNCaP prostate cancer cells and non-malignant HEK-293 cells. [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA showed high stability, PSMA binding "],"journal":["International journal of molecular sciences"],"pubmed_title":["Development and In Vitro Evaluation of [&lt;sup&gt;64&lt;/sup&gt;Cu]Cu-NOTA-TP-PSMA, a Novel Radiotheranostic Agent Against Prostate Cancer."],"pmcid":["PMC12692291"],"funding_grant_id":["NFRFT-2022-00269"],"pubmed_authors":["Ignatius Arokia Doss PM","Ait-Mohand S","Talebian H","Sanche L","Guerin B"],"additional_accession":[]},"is_claimable":false,"name":"Development and In Vitro Evaluation of [&lt;sup&gt;64&lt;/sup&gt;Cu]Cu-NOTA-TP-PSMA, a Novel Radiotheranostic Agent Against Prostate Cancer.","description":"Prostate cancer (PCa), particularly in its metastatic form, remains a major clinical challenge due to limited diagnostic and therapeutic options. To address this, we developed a novel radiotheranostic agent, [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA, by conjugating a prostate-specific membrane antigen (PSMA) ligand to a <sup>64</sup>Cu-radiolabeled terpyridine-platinum (TP) compound previously shown to exert selective cytotoxicity against cancer cells. In this study, the biological performance of [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA was compared with the monomeric analogs [<sup>64</sup>Cu]Cu-NOTA-PSMA and [<sup>64</sup>Cu]Cu-NOTA-TP through in vitro studies in PSMA-positive LNCaP prostate cancer cells and non-malignant HEK-293 cells. [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA showed high stability, PSMA binding ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-05-26T11:01:42.72Z","creation":"2026-05-24T03:11:15.956Z"},"accession":"S-EPMC12692291","cross_references":{"pubmed":["41373803"],"doi":["10.3390/ijms262311651"]}}